Sylvia Taylor of Novavax discusses how new vaccine technologies are reducing side effects, lowering costs, and enhancing immune response.
Sylvia Taylor
Advertisement
Sylvia Taylor is EVP of corporate affairs and head of Novavax Sweden for Novavax.
Articles by Sylvia Taylor
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ
2
How Basket-Trials are Reshaping Drug Development Timelines
3
Accelerating Speed to Patient: A Conversation With Eli Lilly’s Sarah O’Keeffe
4
China Pharma Trends: Premium Pricing and Priority Access for True Innovations
5